ARTICLES BY LOUIS

• Autonomous Decision-Making: Are We Ready For Agentic AI

  1/15/2025

  The biopharma industry has generative artificial intelligence (AI) in its employ. After a long wait, we’ve adopted it rather suddenly. Just in time for a new kid in town. Next to ride in is Agentic AI. It will more robustly revolutionize our drug development and manufacturing. A preview of what's to come.

• It's Partly Personal (Medicine): In 10 Years Outsourcing At $315 Billion

  1/13/2025

  You’ve got to give Towards Healthcare credit. They've the fortitude to publish a 10-year projection of how much development and manufacturing outsourcing will add up to globally. Interestingly, personalized medicine may play an outsized role in that growth. Chief Editor Louis Garguilo takes a deeper dive into the Pharmaceutical CDMO Market Companies, Advantages and Segmental Analysis.

• 2024 Made Us Nervous. Will 2025 Be A Happier New Year?

  1/6/2025

  Chief Editor Louis Garguilo doesn't recall a time of more collective concern over development and manufacturing outsourcing than exhibited during last year's news of Novo Holdings’ purchase of Catalent, and the sale of certain Catalent facilities to Novo Nordisk. That angst was aggravated by the simultaneous drama known as the BIOSECURE Act. Will we have a calmer 2025?

• 2025: Navigating Partnerships Amid Political And Economic Shifts

  1/2/2025

  Brace for a potentially turbulent 2025. That’s the collective message members of the Outsourced Pharma Editorial Advisory Board provided Chief Editor Louis Garguilo for his first editorial of 2025. They reveal a landscape where geopolitical tensions, regulatory evolutions, and emerging technologies will affect how you develop and manufacture drugs.

• 2024 Review: It Was Your Moment In Outsourcing History

  12/17/2024

  Chief Editor Louis Garguilo writes that 2024 sent us a harsh reminder: None of us are paragons of outsourcing sagacity. We need to keep learning, and updating. And staying aware that the outside world – history in the making– interferes. Here's a review of a historic year that will get you thinking: How did I create outsourcing history in 2024?

• Biotechs Should Go With An Uber Not A Limo

  12/12/2024

  Bob Discordia had been in stealth mode for a while. When he finally emerged, Chief Editor Louis Garguilo knew his newco would include a precise model of outsourcing. The reveal came earlier this year with the announcement he had founded EQUULUS Therapeutics, a neuroscience biotech. So how will Discordia outsource? He'll take an Uber ... and advises you do the same.

• Every CDMO Is Perfect Before The Project Starts

  12/9/2024

  Jin-an Jiao, VP, Process and Analytical Development, Synthekine, has worked with CDMOs around the world. "When you talk with them about starting a new project," he says, "everybody's perfect. Everybody's great.” Unfortunately, that can change quickly, and thus the need to confirm "a real commitment to timelines." Part 3 and our final discussion with Jiao ...

• One Percent Of A Hundred People's Efforts

  12/5/2024

  Persephoni BioPartners CEO Hilary Shultz, and newly hired Chief Scientific Officer William Heath – a 34-year veteran of Eli Lilly – explain their biotech-forming business model, dubbed a venture studio, and provide sound advice on working with CDMOs.

• Go Ahead, Outsource Your Entire Biotech

  12/2/2024

  Persephoni BioPartners CEO Hilary Schultz has created a business model that may propel “externalization” to an ultimate implementation: The formation of a biotech by outsourcing the entire organization, which then outsources to advance an asset. Schultz describes Persephoni as a venture studio. Chief Editor Louis Garguilo investigates further ...

• More AI But Fewer Process Chemists?

  11/25/2024

  Artificial intelligence (AI) has made its way to the midsection of our new-drug life cycle. AI now directly enables route-scouting and data scientists. The enabling is happening at drug sponsors and at your CDMOs. What does this look like in practice? Will there be fewer process chemists in the future, and who will they be?